Masthead-Image-Right-min

Beyond the Deal: RCM Pitfalls That Can Undermine Lab M&A Success

Ensure success by addressing critical RCM integration pitfalls that can disrupt post-close performance and erode confidence. 

Continue Reading...

The End of an Era: FDA is Rescinding Long-Contested LDT Rule for Labs

Withdrawal of LDT Rule Provides Regulatory Clarity and Reimbursement Guidance for Laboratories

Continue Reading...

In our Back to School Era: Grading Revenue Cycle Vendors Like a Pro

Score Your EDI Clearinghouse Partners: Boost Efficiency and Say Goodbye to Low Marks.

Continue Reading...

UnitedHealth Group's Turmoil: The Impact on Labs and Pathology Groups

Rising costs, regulatory scrutiny, and shifting payer dynamics could reshape lab and pathology practice operations and reimbursements.

Continue Reading...

From Red Flags to Readiness: How Labs Can Stay Ahead of Audit Risks

With $1.2B in improper lab payments projected, payers are ramping up audits—putting clinical labs under intense scrutiny.

Continue Reading...